Compass Therapeutics (NASDAQ:CMPX) Releases Earnings Results, Beats Expectations By $0.03 EPS

Compass Therapeutics (NASDAQ:CMPX) announced its quarterly earnings results on Tuesday. The company reported ($0.08) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.11) by $0.03, Zacks reports.

Compass Therapeutics Stock Performance

Shares of Compass Therapeutics stock traded down $0.02 during midday trading on Wednesday, hitting $1.78. The company had a trading volume of 68,712 shares, compared to its average volume of 431,284. The company has a 50 day moving average of $1.75 and a 200 day moving average of $1.41. Compass Therapeutics has a 52-week low of $0.77 and a 52-week high of $2.34. The stock has a market capitalization of $244.22 million, a P/E ratio of -4.80 and a beta of 0.92.

Analyst Upgrades and Downgrades

Several research analysts have recently issued reports on the company. HC Wainwright reissued a “buy” rating and issued a $10.00 target price on shares of Compass Therapeutics in a research report on Monday. Wedbush reiterated an “outperform” rating and issued a $8.00 price objective on shares of Compass Therapeutics in a report on Wednesday, August 7th. Finally, LADENBURG THALM/SH SH upgraded shares of Compass Therapeutics from a “neutral” rating to a “buy” rating and set a $5.00 target price on the stock in a report on Monday, September 16th.

About Compass Therapeutics

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.